apatinib-based therapies

apatinib · Adagene / Jiangsu Hengrui Medicine (depending on formulation; ASP often associated with Hengrui)

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for apatinib-based therapies, covering 2023-04-21 to 2023-04-21. Get the full timeline:

Most recent: Clinical Trial Update: Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma [Phase 2]

See pricing